AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...

The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...

The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...